Aurinia Pharmaceuticals (AUPH) Prepaid Assets (2016 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Prepaid Assets came in at $4.1 million in Q1 2026, down 25.58% YoY from $5.5 million in Q1 2025, and down 28.32% on a QoQ basis from $5.7 million in Q4 2025.
Analysis
Aurinia Pharmaceuticals (AUPH) Prepaid Assets (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 11 years of Prepaid Assets data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Prepaid Assets fell 25.58% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 25.58% YoY) and the FY2025 annual result came in at $5.7 million, up 408.95% from the prior year.
- Prepaid Assets declined to $4.1 million in Q1 2026, from $5.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $17.4 million in Q2 2022 to a low of $301000.0 in Q3 2025.
- A 5-year average of $5.6 million and a median of $4.1 million in 2026 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 739.82% — and 2025, when it tumbled 97.82%.
- Tracing AUPH's Prepaid Assets over 5 years: stood at $1.3 million in 2022, then retreated by 22.71% to $1.0 million in 2023, then climbed by 9.51% to $1.1 million in 2024, then soared by 408.95% to $5.7 million in 2025, then fell by 28.32% to $4.1 million in 2026.
- The last three Prepaid Assets figures came in at $4.1 million (Q1 2026), $5.7 million (Q4 2025), and $301000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.10 Bn | 1.66 Bn | 76.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.53 Mn |
| Mar 31, 2026 | 4.12 Mn |
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 11.11 Mn |
| Jun 30, 2025 | 6.58 Mn |
| Mar 31, 2025 | 5.54 Mn |
| Dec 31, 2024 | 11.22 Mn |
| Sep 30, 2024 | 13.82 Mn |
| Jun 30, 2024 | 7.84 Mn |
| Mar 31, 2024 | 7.65 Mn |
| Dec 31, 2023 | 9.49 Mn |
| Sep 30, 2023 | 16.16 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Mar 31, 2023 | 10.10 Mn |
| Dec 31, 2022 | 13.58 Mn |
| Sep 30, 2022 | 12.16 Mn |
| Jun 30, 2022 | 17.42 Mn |
| Mar 31, 2022 | 12.20 Mn |
| Dec 31, 2021 | 11.71 Mn |
| Sep 30, 2021 | 13.71 Mn |